Dr. Amanda Haidet-Phillips is the Executive Director, Global Program Team Leader for Sarepta Therapeutics where she leads cross-functional program teams to bring gene therapies from the laboratory to patients with rare, neuromuscular diseases. Prior to Sarepta, Dr. Haidet-Phillips worked in pharma and biotech as part of AveXis and then Novartis Institute for BioMedical Research to help transition gene therapy products from the pre-clinical proof of concept stage in R&D to first-in human trials.

Prior to joining industry, Dr. Haidet-Phillips served as Scientific Portfolio Director for the Muscular Dystrophy Association where she led the strategic management of research grants and investments for motor and peripheral nerve diseases. Dr. Haidet-Phillips completed a post-doctoral fellowship at Johns Hopkins University seeking to understand the causes of ALS and develop new therapeutic approaches for the disease. She received her Ph.D from The Ohio State University where she helped to develop gene therapies for neuromuscular disease.